GH Pitié-Salpêtrière-Charles Foix
Welcome,         Profile    Billing    Logout  
 4 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spano, Jean-Philippe
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Spano, Jean-Philippe
INJECTABL-1, NCT05688280 / 2022-000176-19: Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS

Active, not recruiting
1/2
42
Europe, US
1.0% IP-001 for Injection, IP-001
Immunophotonics, Inc., Immunophotonics Inc.
Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
02/25
02/25
KEYNOTE-E72, NCT06016920: Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma

Recruiting
1/2
51
Europe, RoW
VB10.16, Pembrolizumab, KEYTRUDA®
Nykode Therapeutics ASA, Merck Sharp & Dohme LLC
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
09/27
01/28
REPARP, NCT05378204: Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Recruiting
N/A
120
Europe
Main study:, Sub-study:
Institut Claudius Regaud, Artios Pharma Ltd
Breast Cancer
01/27
06/27

Download Options